IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
CXCR4 is a good survival prognostic indicator in multiple myeloma patients
Bao, Li; Lai, Yueyun; Liu, Yanrong; Qin, Yazhen; Zhao, Xiaosu; Lu, Xijing; Jiang, Qian; Lu, Jin; Huang, Xiaojun
关键词Multiple myeloma SDF-1 alpha CXCR4 Survival Bone marrow cells
刊名LEUKEMIA RESEARCH
2013-09-01
DOI10.1016/j.leukres.2013.06.002
37期:9页:1083-1088
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Hematology
研究领域[WOS]Oncology ; Hematology
关键词[WOS]STEM-CELL TRANSPLANTATION ; HIGH-DOSE CHEMOTHERAPY ; IN-SITU HYBRIDIZATION ; PLASMA-CELLS ; GENETIC ABNORMALITIES ; DISEASE PROGRESSION ; C-KIT ; EXPRESSION ; BORTEZOMIB ; PHASE-3
英文摘要

SDF1 alpha and its receptor CXCR4 are involved in multiple myeloma (MM) by attracting and activating plasma cells in the bone marrow. CXCR4 expression in MM cells is inversely correlated with disease activity. The aim of this study was to evaluate CXCR4 as a prognostic tool in MM, as well as other markers of disease, such as chromosomal aberrancies. Purpose was to investigate the expression levels of SDF-1 alpha before and after bortezomib and thalidomide treatment. From February 2006 to April 2012, CXCR4 expression was prospectively assessed in bone marrow samples from a large population of patients( n = 227) using flow cytometry. Clinical characteristics were collected and chromosomal aberrancies were assessed in 144 patients. SDF-1 alpha levels were determined using ELISA in peripheral blood samples from 40 patients before and after chemotherapy. Our results show that CXCR4 was present in 43.2% (98/227) of newly diagnosed MM patients and that CXCR4 expression was significantly correlated with CD117( P < 0.05). CXCR4-positive MM patients had a significantly longer estimated survival time than CXCR4-negative patients (median of 48 vs. 42 months, P < 0.05). Multivariate survival analyses identified that the +1q21/CXCR4- phenotype is an independent survival predictor, along with the International Staging System (ISS) stage. No significant difference was observed in expression levels of SDF-1 alpha before and after bortezomib/thalidomide treatment. In conclusion, +1q21/CXCR4- could be an independent survival prognosis predictor in MM patients. Expression levels of SDF-1 alpha before and after bortezomib/thalidomidetreatment are not different, although they are higher than in controls. (C) 2013 Published by Elsevier Ltd.

语种英语
WOS记录号WOS:000324097600017
引用统计
被引频次:17[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63364
专题北京大学第二临床医学院_血液科
作者单位Peking Univ, Inst Hematol, Peking Univ Peoples Hosp, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Bao, Li,Lai, Yueyun,Liu, Yanrong,et al. CXCR4 is a good survival prognostic indicator in multiple myeloma patients[J]. LEUKEMIA RESEARCH,2013,37(9):1083-1088.
APA Bao, Li.,Lai, Yueyun.,Liu, Yanrong.,Qin, Yazhen.,Zhao, Xiaosu.,...&Huang, Xiaojun.(2013).CXCR4 is a good survival prognostic indicator in multiple myeloma patients.LEUKEMIA RESEARCH,37(9),1083-1088.
MLA Bao, Li,et al."CXCR4 is a good survival prognostic indicator in multiple myeloma patients".LEUKEMIA RESEARCH 37.9(2013):1083-1088.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Bao, Li]的文章
[Lai, Yueyun]的文章
[Liu, Yanrong]的文章
百度学术
百度学术中相似的文章
[Bao, Li]的文章
[Lai, Yueyun]的文章
[Liu, Yanrong]的文章
必应学术
必应学术中相似的文章
[Bao, Li]的文章
[Lai, Yueyun]的文章
[Liu, Yanrong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。